Being diagnosed with a malignant brain tumor is devastating news for patients and their loved ones. Whereas some types of tumor respond well to treatment, others such as glioblastomas – the most common and aggressive brain tumors – are known to recur and progress within short times from the diagnosis. Patients diagnosed with this type of cancer, and who undergo current standard treatment, have a median survival of 16 months.
Montreal, Quebec and Vancouver, British Columbia – Working together to accelerate research into neurological diseases, three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and Parkinson’s disease.
Discovery could be key to treating brain and spinal cord injury
A foray into plant biology led one researcher to discover that a natural molecule can repair axons, the thread-like projections that carry electrical signals between cells. Axonal damage is the major culprit underlying disability in conditions such as spinal cord injury and stroke.
Research and clinical care complement each other at The Neuro
February 28th was Rare Diseases Day, an opportunity to recognize a class of disease that is often overlooked. In the past five years, the Montreal Neurological Institute and Hospital (The Neuro) has made the study and treatment of rare diseases a major priority, hiring new specialists and support staff and coordinating activity under a new research group.
A new mouse model with a working immune system could be used in laboratory research to improve understanding of Zika virus infection and aid development of new treatments, according to a study published in PLOS Pathogens.
CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research
CQDM and Brain Canada are proud to announce the funding of two new multi-disciplinary and multi-institutional research projects under the second edition of their Focus on Brain strategic initiative. The partners will award a total of $3M to two research teams to develop cutting-edge tools, technologies and platforms designed to accelerate the discovery of new drugs for brain and nervous system disorders.
Project will enhance mental health access for multicultural communities
On Jan. 18, 2017, Bell Let’s Talk announced a donation of $250,000 to McGill University’s Montreal Neurological Institute and Hospital – known as The Neuro – to fund the development of online mental health resources focused on the needs of multicultural communities.
An all-star lineup of experts in the fields of sports and neurology will share a stage on Jan. 27 to discuss concussions, a serious injury that has only recently been getting the attention it deserves.
Olivia Oxlade, one of the authors is an epidemiologist at McGill University’s TB centre. http://alturl.com/zzqby
Have you ever met someone who just wasn’t into music? They may have a condition called specific musical anhedonia, which affects three-to-five per cent of the population.
Researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of McGill University have discovered that people with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward.
Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Study tracks patients to better understand effects and possible treatments
December 1 is World AIDS Day, a time to raise awareness about a disease that has afflicted 70 million people worldwide, 35 million of whom have died as a result.
Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells.
Two researchers at the Montreal Neurological Institute and Hospital (MNI) of McGill University have received funding to study a devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk.
MNI scientists will study stem cells, genetic mutations to develop new treatments
Researchers at the Montreal Neurological Institute of McGill University who are playing key roles in uncovering the mechanisms underlying ALS will share in $3.9 million in research funding, part of $4.5 million announced on Nov. 23 by the ALS Society of Canada in partnership with Brain Canada.